Navigation Links
Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms

BURLINGTON, Mass., Aug. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of COPD,  physicians in Brazil and Mexico manage to follow clinical guidelines and commonly prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist (LAMA)- containing regimens, although they do so within current severe cost/coverage constraints. Therefore, new brands of LABA/LAMA fixed-dose combinations (FDCs) that are expected to launch in these countries—which will considerably expand the chronic obstructive pulmonary disease (COPD) market—will compete with well-established marketed therapies, especially the twice-daily LABA/ inhaled corticosteroids (ICS) FDCs. New LABA/LAMA FDCs will also compete with recently launched once-daily Relvar/Relvare (GlaxoSmithKline/Theravance). According to payers, improvements in dosing and delivery of new FDCs of current drugs/drug classes are important but may not be enough to justify a premium price over comparator drugs or its separate components.

Other key findings from the Emerging Markets Physician and Payer Forum report entitled Positioning of Current and Emerging Agents for COPD: Physician and Payer Perspectives on the Prescribing and Patient Access Landscape in Brazil and Mexico include:

  • Factors impacting formulary inclusion: In Brazil, CONITEC (Brazil's HTA agency) is restricting the incorporation of new COPD drugs in the coverage offered by the public healthcare system. Demonstration of superior comparative clinical and economic benefit, preferably using local data, is crucial to formulary inclusion.
  • Exclusion of key agents: In Mexico, although the national drug formulary lists a comprehensive range of COPD drugs that can be covered by government-sponsored or Social Security programs, individual institutions have been excluding some key agents based on their own budgets.
  • Private patients' access to treatment: The budgetary environment seems less restrictive in the private sector than in the public sector, but the lack of coverage in the outpatient setting in Brazil and of mandatory coverage in Mexico—together with expensive out-of-pocket costs in both countries—is limiting some eligible COPD private patients' access to treatment.

Comments from Decision Resources Group Director Andreia Ribeiro, Ph.D.:

  • "Upon the launch of generic LABA/ICS FDCs (GlaxoSmithKline's Seretide and AstraZeneca's Symbicort) and LAMAs (Boehringer Ingelheim's Spiriva), their use is likely to be promoted, due to the tendering purchase models used in the public sector in both countries. COPD patients in Brazil and Mexico are already requesting currently available low-priced generics, according to our survey findings." 
  • "Particularly in Brazil, state coverage and judicial actions are a powerful driver of access to costly agents, especially those not included in the formularies. Also, in some cases, patient assistance programs are the only way for patients to access drugs not covered under a specific public sector scheme, as in the case of Seguro Popular in Mexico. Manufacturers should explore these opportunities to best position their drugs in these markets."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources Group
Christopher Comfort

Logo -

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema
2. Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End
3. The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics
4. Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
5. FDA Grants Fast Track Designation to CTI BioPharmas Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
6. Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
7. Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
8. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
9. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
10. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
11. ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
Breaking Medicine News(10 mins):